<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00535405</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-128</org_study_id>
    <secondary_id>2007_588</secondary_id>
    <nct_id>NCT00535405</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Shering-Plough JV Study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus
      atorvastatin in elderly patients with high cholesterol at high or moderately high risk for
      coronary heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved LDL-C &lt;70 mg/dL at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C &lt;100 mg/dL or Patients With AVD Who Achieved LDL-C &lt;70 mg/dL at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Patients with AVD Who Achieved LDL-C &lt;70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved LDL-C &lt;100 mg/dL at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With High Risk for CHD Who Achieved LDL-C &lt;70 mg/dL at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Risk was assessed utilizing a history of established CHD or CHD risk equivalent and Framingham Risk scoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With AVD Who Achieved LDL-C &lt;70 mg/dL at Week 12</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Patients with AVD Who Achieved LDL-C &lt;70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1289</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 1 active treatment dose &amp; 2 Placebo (Pbo) doses or 2 active treatment doses &amp; 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 1 active treatment dose &amp; 2 Pbo doses or 2 active treatment doses &amp; 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 1 active treatment dose &amp; 2 Pbo doses or 2 active treatment doses &amp; 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 1 active treatment dose &amp; 2 Pbo doses or 2 active treatment doses &amp; 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 1 active treatment dose &amp; 2 Pbo doses or 2 active treatment doses &amp; 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 10 mg</intervention_name>
    <description>Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10 mg/simvastatin 20 mg</intervention_name>
    <description>Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg</intervention_name>
    <description>Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10 mg/simvastatin 40 mg</intervention_name>
    <description>Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40 mg</intervention_name>
    <description>Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a cholesterol level of 130 mg/dL or greater

          -  Patient is willing to maintain a cholesterol lowering diet for as long as they are in
             the study

          -  Patient is at moderate high risk or high risk for coronary heart disease per the
             National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII)
             guidelines

        Exclusion Criteria:

          -  Patient weighs less than 100 lbs

          -  Patient has an allergy to ezetimibe, simvastatin or atorvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Cardiol. 2010 Nov 1;106(9):1255-63. doi: 10.1016/j.amjcard.2010.06.051.</citation>
    <PMID>21029821</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2007</study_first_submitted>
  <study_first_submitted_qc>September 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <results_first_submitted>April 26, 2010</results_first_submitted>
  <results_first_submitted_qc>April 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2010</results_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase III
First Patient In 08-Nov-2007; Last Patient Last Visit 23-Mar-2009
Eligible patients include drug-naïve patients or patients rendered naïve with the appropriate prior washout at moderately high or high risk for coronary heart disease 65 years and older.</recruitment_details>
      <pre_assignment_details>The study evaluated patients ≥ 65 years of age at moderately high or high risk for Coronary Heart Disease (CHD), with or without atherosclerotic vascular disease. The study was a 3-week single-blind placebo run-in period and a 12-week active treatment period where patients were equally randomized to one of 5 treatment groups for 12 weeks</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin 10 mg</title>
          <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
          <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
          <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>Atorva 40 mg</title>
          <description>Atorvastatin 40 mg once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="259"/>
                <participants group_id="P3" count="259"/>
                <participants group_id="P4" count="257"/>
                <participants group_id="P5" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="241"/>
                <participants group_id="P4" count="235"/>
                <participants group_id="P5" count="241"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin 10 mg</title>
          <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
          <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
          <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Atorva 40 mg</title>
          <description>Atorvastatin 40 mg once daily for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="257"/>
            <count group_id="B2" value="259"/>
            <count group_id="B3" value="259"/>
            <count group_id="B4" value="257"/>
            <count group_id="B5" value="257"/>
            <count group_id="B6" value="1289"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.1" lower_limit="65" upper_limit="94"/>
                    <measurement group_id="B2" value="71.8" lower_limit="65" upper_limit="95"/>
                    <measurement group_id="B3" value="71.7" lower_limit="65" upper_limit="90"/>
                    <measurement group_id="B4" value="72.2" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="B5" value="72.1" lower_limit="65" upper_limit="88"/>
                    <measurement group_id="B6" value="72.0" lower_limit="65" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="175"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="163"/>
                    <measurement group_id="B6" value="809"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="94"/>
                    <measurement group_id="B6" value="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="209"/>
                    <measurement group_id="B4" value="214"/>
                    <measurement group_id="B5" value="210"/>
                    <measurement group_id="B6" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12</title>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
            <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
            <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12</title>
          <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent change in LDL-C</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.5" lower_limit="-41.4" upper_limit="-37.5"/>
                    <measurement group_id="O2" value="-54.2" lower_limit="-56.1" upper_limit="-52.2"/>
                    <measurement group_id="O3" value="-46.6" lower_limit="-48.6" upper_limit="-44.7"/>
                    <measurement group_id="O4" value="-59.1" lower_limit="-61.0" upper_limit="-57.1"/>
                    <measurement group_id="O5" value="-50.8" lower_limit="-52.8" upper_limit="-48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA mixed model with fixed effects for treatment, baseline LDL-C, study week, treatment by study week interaction, and a random subject effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>-12.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA mixed model with fixed effects for treatment, baseline LDL-C, study week, treatment by study week interaction, and a random subject effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>-4.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA mixed model with fixed effects for treatment, baseline LDL-C, study week, treatment by study week interaction, and a random subject effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>-5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
        <time_frame>12 weeks</time_frame>
        <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
            <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
            <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
          <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent of Patients</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="1.92"/>
                    <measurement group_id="O2" value="51.3" spread="3.28"/>
                    <measurement group_id="O3" value="26.1" spread="2.85"/>
                    <measurement group_id="O4" value="68.2" spread="3.03"/>
                    <measurement group_id="O5" value="38.1" spread="3.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.
Generalized Estimating Equations (GEE)</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>12.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.64</ci_lower_limit>
            <ci_upper_limit>20.83</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>3.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.51</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>3.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.39</ci_lower_limit>
            <ci_upper_limit>5.60</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C &lt;100 mg/dL or Patients With AVD Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
        <description>Patients with AVD Who Achieved LDL-C &lt;70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
            <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
            <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C &lt;100 mg/dL or Patients With AVD Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
          <description>Patients with AVD Who Achieved LDL-C &lt;70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.</description>
          <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent of Patients</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="3.20"/>
                    <measurement group_id="O2" value="69.0" spread="3.04"/>
                    <measurement group_id="O3" value="61.3" spread="3.16"/>
                    <measurement group_id="O4" value="82.1" spread="2.50"/>
                    <measurement group_id="O5" value="69.9" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>3.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>4.55</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>1.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>2.87</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved LDL-C &lt;100 mg/dL at Week 12</title>
        <time_frame>12 Weeks</time_frame>
        <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
            <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
            <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved LDL-C &lt;100 mg/dL at Week 12</title>
          <population>Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent of Patients</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="236"/>
                <count group_id="O5" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="3.17"/>
                    <measurement group_id="O2" value="83.6" spread="2.43"/>
                    <measurement group_id="O3" value="76.9" spread="2.73"/>
                    <measurement group_id="O4" value="90.3" spread="1.93"/>
                    <measurement group_id="O5" value="79.5" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>4.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.76</ci_lower_limit>
            <ci_upper_limit>7.24</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>1.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>2.94</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>2.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>4.18</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With High Risk for CHD Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
        <description>Risk was assessed utilizing a history of established CHD or CHD risk equivalent and Framingham Risk scoring.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Patients with High Risk for CHD in the Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
            <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
            <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With High Risk for CHD Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
          <description>Risk was assessed utilizing a history of established CHD or CHD risk equivalent and Framingham Risk scoring.</description>
          <population>Patients with High Risk for CHD in the Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent of Patients</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="2.65"/>
                    <measurement group_id="O2" value="54.3" spread="4.24"/>
                    <measurement group_id="O3" value="28.9" spread="4.01"/>
                    <measurement group_id="O4" value="69.2" spread="4.05"/>
                    <measurement group_id="O5" value="38.2" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>7.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.31</ci_lower_limit>
            <ci_upper_limit>13.42</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>2.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>4.67</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>2.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>3.27</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With AVD Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
        <description>Patients with AVD Who Achieved LDL-C &lt;70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Patients with AVD in the Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin 10 mg</title>
            <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
            <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin 20 mg</title>
            <description>Atorvastatin 20 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
            <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Atorva 40 mg</title>
            <description>Atorvastatin 40 mg once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With AVD Who Achieved LDL-C &lt;70 mg/dL at Week 12</title>
          <description>Patients with AVD Who Achieved LDL-C &lt;70 mg/dL. AVD was defined as a history of myocardial infarction, stable angina, coronary artery procedures or evidence of clinically significant myocardial ischemia.</description>
          <population>Patients with AVD in the Full Analysis Set (FAS). The FAS population includes all randomized patients with baseline (BL) value and at least one valid after-BL value. After-BL measurements up to 3 days following the last dose of double-blind study medication were included in the analysis.</population>
          <units>Percent of Patients</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="3.59"/>
                    <measurement group_id="O2" value="44.4" spread="5.52"/>
                    <measurement group_id="O3" value="31.6" spread="5.23"/>
                    <measurement group_id="O4" value="65.8" spread="5.34"/>
                    <measurement group_id="O5" value="44.4" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>6.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.71</ci_lower_limit>
            <ci_upper_limit>13.38</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>1.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>Reported p-value is multiplicity-adjusted. Hochberg procedure was used to adjust for multiple comparisons.</p_value_desc>
            <method>Logistic Regression using GEE</method>
            <method_desc>Model include terms for treatment, baseline LDL-C, study week and treatment by study week interaction.</method_desc>
            <param_type>Ratio of odds</param_type>
            <param_value>1.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
            <estimate_desc>Ratio of odds of achieving pre-specified LDL-C level on EZ/Simva versus Atorva</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>AE reporting is based on number of subjects at risk. Subjects at risk are randomized subjects who received at least one dose of study drug. Five patients where excluded from the randomized population because they did not receive one dose of study drug (EZ/Simva 20 mg - 3 patients; Atorva 20 mg - 1 patient; Atorva 40 mg - 1 patient).</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin 10 mg</title>
          <description>Atorvastatin (Atorva) 10 mg once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Ezetimibe 10 mg/Simvastatin 20 mg</title>
          <description>Ezetimibe (EZ) 10 mg/simvastatin (Simva) 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Atorvastatin 20 mg</title>
          <description>Atorvastatin 20 mg once daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Ezetimibe 10 mg/Simvastatin 40 mg</title>
          <description>Ezetimibe 10 mg/simvastatin 40 mg once daily for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Atorvastatin 40 mg</title>
          <description>Atorvastatin 40 mg once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AV dissociation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mechanical complication of implant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="256"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="258"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="256"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

